EUR 1,2 billion for vaccine deliver
Kvistgard – The U.S. Department of Health and Human Services has awarded a contract to the Danish-German company Bavarian Nordic A/S for the manufacture and delivery of 20 million doses of the company’s third-generation Modifed Virus Ankara (MVA) smallpox vaccine Imvamune for the US’s Strategic National Stockpile.
The overall deal, including options within the contract, is valued a1,2 billion of which the base contract comprises a370 million. Alongside the delivery of 20 million doses, the money is earmarked in part for investment in further research and development of the vaccine, which will fulfil requirements for a potential use of the vaccine during an emergency case. The money will also be used to fund non-clinical and clinical studies that are necessary for Bavarian Nordic to receive a FDA registration for Imvamune as a vaccine for healthy people. A sum of a820 million is included in the optional part of the contract which is intended to support further clinical studies for the extension of Imvamune’s license to include people infected with HIV, children and the elderly, as well as to procure of up to 60 million additional doses of Imvamune. Bavarian Nordic now hopes, the US contract will pave the way for further deals with other governments.